Skip to content

Development Pipeline

Our next gen products.

Because SonoTran® is truly platform in nature and its use does not require any drug reformulation we’re building a pipeline of revolutionary products comprising both in-house programs and partnered programs utilising both novel drugs and those that are already approved.

If you’re interested in partnering a product with us, or simply finding out more about how SonoTran® could benefit your development program, we’d like to hear from you.

Our pipeline.

Therapeutics / Indication Pre-clinical Phase I/II Pivotal
SonoTran® + Cetuximab & FOLFIRI
/ mCRC
SonoTran® + antibody-based therapeutic
/ Solid Tumours
SonoTran® + Oncolytic Virus
/ Solid Tumours
SonoTran® + Cisplatin
/ HNSCC
In house / available for partnering
Undisclosed partner

Pre-clinical evidence

SonoTran® has been shown to enhance the delivery of multiple oncology agents spanning multiple drug classes, resulting in a significant enhancement of tumour retardation when compared to the oncology agents alone.

Read more in our evidence data sheets for Cetuximab delivery and efficacy data, anti-PDL1, and oncolytic virus.

Clinical investigation: Now recruiting mCRC patients.

SonoTran® is currently being evaluated in a phase I/IIa multicentre clinical investigation in patients with metastatic colorectal cancer (mCRC). The trial includes three patient cohorts to evaluate (a) the safety of the SonoTran® Platform; (b) SonoTran®’s ability to enhance the delivery of cetuximab and irinotecan into tumours in resectable mCRC patients, and (c) SonoTran®’s ability to enhance tumour response to standard of care neoadjuvant chemotherapy (cetuximab + FOLFIRI) in unresectable first line mCRC patients.

Find out more about the ongoing clinical investigation here.

The coordinating investigator of the trial and the Oxford Churchill Hospital site principal investigator is Professor Rachel Kerr (Department of Oncology, University of Oxford). See here.

By harnessing SonoTran®’s unique capabilities, our goal is to dramatically improve the survival outcomes for mCRC patients.

$14bn

Financial burden of colorectal cancer care

Using the most recent available data, costs for cancer care in the US were estimated to be $14 billion in 2020 according to the CDC.

3rd

Colorectal cancer (CRC)

Colorectal cancer (CRC) represents the third most common cancer worldwide and the fourth most common cancer-related cause of death.

15-25%

Metastatic CRC

Approximately 15-25% of patients have metastatic CRC (mCRC) at diagnosis, and nearly half of CRC patients will develop metastases at some point during the course of the disease.

>50%

CRC metastases in the liver

The most common site for CRC metastases is in the liver (more than 50% of patients with metastatic CRC; and in 60% of these patients, liver metastases are the only site of spread).